Answers are grounded in this paper and cite their sources.
Historically, beta-blockers have been considered contraindicated in asthma and chronic obstructive pulmonary disease (COPD) as nonselective beta-blockers have been recorded to cause fatalities in asthma[1] and reports of COPD exacerbations after beta-blocker use. Effect of Beta-blockers on Pulmonary Function in the General Population The Rotterdam study[2]—a prospective population-based cohort study—which is the largest study of the effect of beta-blockers in patients without disease showed that even cardioselective beta-blockers were associated with a lower forced expiratory volume in the first second (FEV1) of 142 mL (95% confidence interval [CI] −189mL, −96 mL). It also showed that after stopping cardioselective beta-blockers FEV1 tended to improve. Beta-blockers in Asthma Effect of Beta-blockers on Pulmonary Function in Asthma A 2002 metanalysis[3] looked at studies going back to the 1970s showed a −9.14% decrease in FEV1 after a single-dose cardioselective beta-blocker (19 studies 240 patients) in mild to moderate asthma. Only four studies with a total of 43 patients looked at longer-term use of cardioselective beta-blockers and found a nonsignificant −3.22% decrease in FEV1. A more recent 2014 systematic review[4] with more precise data showed acute selective beta-blockers in the doses given caused a mean change in FEV1 of −6.9% (95% CI, −8.5 to −5.2), a fall in FEV1 of >20% in one in eight patients (P = 0.03). A dose–response relationship was demonstrated for selective beta-blockers. Selective beta-blockers were better tolerated but not risk free. Effect of Beta-blockers on Asthma Attacks A 2017 retrospective database analysis from the UK Clinical Practice Research Datalink[5] has suggested that mild to moderate asthmatic patients given selective beta-blockers were not more likely to have asthma attacks. Nonselective beta-blocker prescriptions were strongly associated with a 5- to 12-fold increased risk of exacerbations depending on the dose. The limitation of this study is the inherent selection bias of retrospective studies. A more recent 2021 network metanalysis of randomized controlled trials (RCTs)[6] confirmed the high risk of exacerbations with nonselective beta-blockers in patients with a history of asthma but also showed a 3.03 risk ratio (95% CI 1.09–8.41) with the cardioselective beta-blocker metoprolol. Bisoprolol appeared to be safer but very few patients were on this drug. What the Guidelines Say about Beta-blockers in Asthma GINA 2022 Beta-blockers “… should therefore usually be avoided in patients with a history of asthma. When there is no suitable alternative, it may be necessary for a patient with well-controlled asthma, or chronic obstructive pulmonary disease (without significant reversible airways obstruction), to receive treatment with a beta-blocker for a co-existing condition (e.g., heart failure or following myocardial infarction). In this situation, a cardioselective beta-blocker should be selected and initiated at a low dose by a specialist; the patient should be closely monitored for adverse effects.”[7] BTS/SIGN 2019 Beta-blockers, including eye drops, are contraindicated in patients with asthma. Current guidance can be found in the British National Formulary.[8] The current British National Formulary (BNF) states “Decide about prescription of oral or ophthalmic beta-blockers on a case-by-case basis. Initiate treatment under close medical supervision by a specialist. If cardioselective beta-blockers are indicated for acute coronary events, asthma is not an absolute contra-indication, but the relative risks/benefits should be considered.”[9] Beta-blockers in Chronic Obstructive Pulmonary Disease Effect of Beta-blockers on Moderate/Severe Chronic Obstructive Pulmonary Disease In 2001, a study[10] suggested that even in post-myocardial infarction (MI) patients beta-blockers were not beneficial in patients with severe COPD. This was followed by a prospective national study of patients starting long-term oxygen therapy for COPD in Sweden,[11] which confirmed this finding and additionally showed an increase in mortality with beta-blockers in such severe patients with COPD. More recently, a retrospective, registry-based cohort study[12] suggested that moderate to severe COPD outpatients who were treated with beta-blockers for cardiovascular indications had a higher risk of death—this was of borderline significance. There were a plethora of studies, which suggested the beneficial effect of beta-blockers in improving mortality and reducing exacerbations of COPD culminating in a meta-analysis, which suggested the same.[13] There were several flaws with these retrospective studies—marked heterogeneity, publication bias, most studies were nonrandomized and retrospective in design, the diagnosis of COPD relied on physician diagnosis rather than strict clinical criteria, and most studies did not provide pulmonary function or severity of COPD. It is possible that patients treated with beta-blockers may have had less severe baseline COPD or heart failure as data on the presence, phenotype, or severity of COPD and heart failure were not available. Adherence to the prescribed drugs was not recorded raising the possibility of immortal time bias and calendar time bias. The only RCT was performed in 2019[14]—the BLOCK-COPD trial where 50 mg metoprolol was tested in a double-blind placebo-controlled fashion in patients with moderate to severe COPD (mean FEV1 41.1 ± 16.3%, mean smoking exposure 50.1 ± 29.1 pack-years) and an increased risk of exacerbations. The trial was stopped early as the metoprolol group had a higher rate of more severe exacerbation than the placebo group, with a rate ratio of 1.51 (95% CI, 1.00–2.29) for severe exacerbation and 3.71 (95% CI, 1.10–16.98) for very severe exacerbation. There was a trend toward increased mortality in the metoprolol group, but the numbers were insufficient to reach statistical significance—there were 11 deaths in the metoprolol group and 5 in the placebo group, with unadjusted and adjusted hazard ratios for the death of 2.18 (95% CI, 0.76–6.29) and 2.13 (95% CI, 0.69–6.42), respectively. The majority of deaths in the metoprolol group were attributed to COPD (7 vs. 1 in the placebo group). These patients did not have any indication of beta-blockers for cardiovascular protection. Summary of the Evidence for Beta-blocker Use in Chronic Obstructive Pulmonary Disease It is clear that moderate to severe patients with COPD have worse outcomes even if cardioselective beta-blockers such as metoprolol are used in the absence of any cardiovascular mortality risk reduction.[14] Risk–benefit ratio improves with lessening the severity of COPD and well-defined indications for beta-blockers with no equally effective therapeutic alternatives—perhaps limited to heart failure with reduced ejection fraction and post-MI.[15–[15–17] In mild COPD with a low risk of exacerbations, the risk–benefit ratio of using beta-blockers is improved and indications may be relaxed. Individualization of treatment must be achieved with optimal treatment of COPD avoiding beta-blockers where equally effective alternatives exist. Perhaps ongoing RCTs[18] with bisoprolol, a more cardioselective beta-blocker, if positive will push the balance toward more liberal use of these drugs in COPD. Use of Beta-blockers in Asthma/Chronic Obstructive Pulmonary Disease Not an absolute contraindication Use where there is no suitable alternative for approved indications only (e.g., heart failure with reduced ejection fraction or post-MI) Only in well-controlled disease (aggressively control Obstructive Airways Disease (OAD) before initiation) Cardioselective beta-blockers (bisoprolol preferred to metoprolol) Nonselective beta-blockers are contraindicated. Initiate at a low dose (start low go slow) Overseen by a specialist Closely monitored
No takes yet. Share an insight, caveat, or question.
Sumit Sengupta (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: